# Tioma Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tioma-therapeutics

- Industry: Pharmaceuticals
- Headquarters: St. Louis, US
- Website: www.tiomatherapeutics.com
- Total disclosed funding: $86M
- Latest round: Series A (Aug 16, 2016)
- Investors on record: 4

## About

Based in the US, Tioma Therapeutics, formerly known as Vasculox, focuses on immuno-oncology and developing anti-CD47 antibodies to treat solid and hematologic cancers. The company was founded by William Frazier, a professor of Biochemistry, Molecular Biophysics, Cell Biology, and Biomedical Engineering at Washington University School of Medicine. John Donovan is the president and CEO of the company. In August 2016, new investors Novo Ventures, RiverVest Ventures, Roche Venture Fund and SR One co-led USD 86 million in a Series A funding round for Tioma Therapeutics, Inc.

## Funding rounds

- Series A, Aug 16, 2016, $86M — RiverVest Ventures Partners, SR One, Novo Holdings, Roche Venture Fund

## Investors

- RiverVest Ventures Partners (https://capitalatlas.ai/funds/rivervest-ventures-partners) — Series A
- SR One (https://capitalatlas.ai/funds/sr-one) — Series A
- Novo Holdings — Series A
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series A